Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.
European Neuropsychopharmacology, August 2017
—
Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies…
American Journal of Obstetrics and Gynecology, August 2017
—
To the Editors: We read with interest the article by Chasnoff, 1 which concluded that physicians should be educated about the negative effects of marijuana use during pregnancy and should discourage its use by pregnant women and women considering becoming pregnant. In our view…
PLoS One, 10 July 2017
—
The endocannabinoid system is a regulatory pathway consisting of two main types of cannabinoid receptors (CB1 and CB2) and their endogenous ligands, the endocannabinoids. The CB1 receptor is highly expressed in the central and peripheral nervous systems (PNS) in mammalians and…
Cannabis and Cannabinoid Research, 1 June 2017
—
Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with o…
Alcohol & Drug Abuse Institute, University of Washington, June 2017
—
THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…
Epilepsy & Behavior, May 2017
—
Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…
Expert Opinion on Pharmacotherapy, April 2017
—
Neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are s…
Frontiers in Pharmacology, 3 February 2017
—
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do…
Cannabis and Cannabinoid Research, February 2017
—
The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…
Pharmacological Research, January 2017
—
The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis…
Methods in Enzymology, 2017
—
The increase in lifespan during the last 50 years, mainly in developed countries, has originated a progressive elevation in the incidence of chronic neurodegenerative disorders, for which aging is the key risk factor. This fact will definitively become the major biomedical cha…
Stroke, January 2017
—
BACKGROUND AND PURPOSE: Stroke is a leading cause of adult disability characterized by physical, cognitive, and emotional disturbances. Unfortunately, pharmacological options are scarce. The cannabinoid type-2 receptor (CB2R) is neuroprotective in acute experimental stroke by …